The aims of this study were to investigate the contributions of the mitochondrial DNA m.4216T > C and m.4917A > G variants, and also of the European-specific mitochondrial cluster J/T, to the development of type 2 diabetes mellitus in Caucasian-Brazilian patients from Southern Brazil. We analyzed 347 type 2 diabetes patients and 350 control subjects. Variant frequencies in patients and control subjects were compared using χ 2 tests or odds ratio. We also compared clinical and laboratory characteristics among patients with and without the variants. We found that the frequencies of the m.4216T > C and m.4917A > G variants are higher in diabetic patients than in control subjects. Moreover, haplogroups J (partially defined by the presence of the m.4216T > C variant only) and T (partially defined by the presence of both m.4216T > C and m.4917A > G variants) are more frequent in the type 2 diabetic group than in the control group. Patients belonging to the cluster J/T are more insulin resistant than patients of other haplogroups. In conclusion, our results indicate the association of the cluster J/T (as suggested by analyses of the m.4216T > C and m.4917A > G variants) with insulin resistance and type 2 diabetes.
Introduction
Type 2 diabetes mellitus (DM) seems to be maternally transmitted in some families and a mitochondrial origin has been postulated (Alcolado & Alcolado, 1991; Thomas et al. 1994) . Since mitochondrial oxidative phosphorylation (OXPHOS) plays an important role in glucose-stimulated insulin secretion in beta cells, defects in mitochondrial genes are plausible causative agents for DM (Kadowaki et al. 1994 ). An A to G substitution at position 3243 of the mitochondrial tRNA Leu(UUR) gene is the most commonly reported defect associated with DM. This variant was first described as being associated with the encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome (Goto et al. 1990) , and was more recently recognized as a cause of the maternally inherited DM and deafness (MIDD) syndrome (Reardon et al. 1992; van den Ouweland et al. 1992) . Nevertheless, the m.3243A > G variant has been reported in only 1-2% of patients with type 2 DM (Gerbitz et al. 1995) .
Recently, a number of other mitochondrial variants have been reported in some families presenting maternal transmission of type 2 DM (Alcolado et al. 2002) . However, an important question is the prevalence of these variants amongst patients with type 2 DM. Taking this into consideration, Perucca-Lostanlen et al. (2000) reported that in a group of French patients with features of MIDD 66.0% had a T to C substitution at position 4216 of the NADH-dehydrogenase (ND) subunit 1 gene (m.4216T > C variant), and 55.0% had an A to G substitution at position 4917 of the ND subunit 2 gene (m.4917A > G variant). However the authors found these variants in similar frequencies in both the type 2 diabetic group (8.3% for the m.4216T > C variant and 4.2% for the m.4917A > G variant) and the control group (12.3% for the m.4216T > C variant and 9.2% for the m.4917A > G variant). Both m.4216T > C and m.4917A > G variants cause an amino acid change in the MT-ND1 (Tyr/His) and MT-ND2 (Asp/Asn) gene products, respectively, and are homoplasmic. Nonetheless, these variants have not been investigated in other diabetic populations, but have been described as secondary mutations involved in the pathogenesis of Leber's hereditary optic neuropathy (LHON) (Carelli et al. 2003) , and as neutral polymorphisms in linkage with a common European-specific mitochondrial cluster (haplogroups J and T) (Herrnstadt et al. 2002) . Following on from these studies, we decided to investigate the contributions of the m.4216T > C and m.4917A > G variants, and of the haplogroups J and T, to the development of type 2 DM in Caucasian-Brazilian patients from Southern Brazil.
Materials and Methods

Subjects
This case-control study was carried out with 347 unrelated Caucasian-Brazilian type 2 diabetic patients who are participating in a multicentre study in the Brazilian State of Rio Grande do Sul. Type 2 DM was diagnosed according the criterion of The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997). The non-diabetic control group was composed of 350 Caucasian-Brazilian subjects with normal fasting plasma glucose, without any known chronic diseases, and collected from the same hospitals as the patients. Ethnic definition was based on self report. Subjects with uncertain ethnic definition were excluded from the study. In summary, the studied subjects descend from European populations, especially from Portugal, Spain, Italy, and Germany. Written informed consent was obtained from all subjects and the study was approved by the Hospitals' Ethical Committees.
All patients underwent a standardized clinical and laboratory evaluation. Sitting blood pressure (BP) was measured twice after a 5-min rest using a mercury sphygmomanometer. The mean value of two measurements was used to calculate systolic and diastolic BP. Hypertension was defined as BP levels ≥ 140/90 mmHg or the use of antihypertensive drugs. Weight and height were used to calculate body mass index (kg/m 2 ). Diabetic retinopathy was assessed by ophthalmoscopic examination and classified as absent, nonproliferative, or proliferative. Renal status was based on the albumin excretion rate (AER) in at least two out of three consecutive 24-h timed collections. Patients were classified as normo-(AER < 20 μg/min), micro-(AER 20-199 μg/min), or macroalbuminurics (AER > 200 μg/min). The diagnosis of distal sensory neuropathy was based on abnormal results of Achilles tendon reflexes and vibration or sensory perception. Insulin resistance was estimated according to homeostasis model assessment (HOMA): fasting serum insulin (pmol/l) × fasting plasma glucose (mmol/l)/22.5, in a subgroup of 120 patients not having insulin therapy and with serum creatinine <132 μmol/l.
Laboratory Methods
Blood glucose was determined using the glucose oxidase method; serum creatinine by the Jaffé reaction; glycated haemoglobin (HbA1c) by ion-exchange HPLC (Merck-Hitachi L-9100 GhB Analyser, reference range: 4.7-6.0%); total plasma cholesterol and triglycerides by enzymatic methods; urinary albumin concentration by immunoturbidimetry (Sera-Pak immuno microalbuminuria, Bayer, Tarrytown, NY); C-peptide levels by radioimmunoassay (Diagnostic System Laboratories Incorporation, Webster, USA); and serum insulin by electrochemiluminescence (Elecsys R Systems/2010 -ROCHE, sensitivity 0.2 uUI/mL, mean intra-and interassay CV: 2.0 and 5.96%, reference range 2.6-24.9 uUI/mL). length polymorphism analysis and polyacrylamide gel electrophoresis. To detect the m.4216T > C variant, we subjected DNA samples to PCR with the forward primer 5 ACTCACCCTAGCATTACTTATATCA3 (np4191-4215) and reverse primer 5 ATTTAGCTG-ACCTTACTTTACGATG3 (np4384-4418). The underlined position in the first primer represents a modification from the wild-type sequence to create an NdeI restriction site in this sequence: the 228bp PCRfragment of the wild-type allele can then be cleaved into two fragments of 203bp and 25bp. For the screening the m.4917A > G variant we used the forward primer 5 TACCAAATCTCTCCCTCACTC3 (np4896-4916) and the reverse primer 5 ATGGTT-ATGTTAGGGTTGTACG3 (np5053-5074). The underlined nucleotide creates a TaqI restriction site in the m.4917A > G mutant sequence: the 179bp PCRfragment can then be cleaved into two fragments of 157bp and 22bp. All experiments involving enzymatic digestion were carried out with positive control samples, whose genotypes were known following automated sequencing of the PCR fragment. In addition, we also sequenced a selection of subjects without the two variants (n = 20) to ensure they were not false-negatives. Duplicate samples were assessed for every subject in different gel loadings. In rare cases of ambiguous readins, sequencing of the PCR product was conducted in a MegaBace 1000 (GE HealthCare) system. The m.4216T > C variant is reported to be one of the defining polymorphisms for the mtDNA cluster J/T (Finnila et al. 2001; Herrnstadt et al. 2002) . It can occur in association with the m.4917A > G variant (in part defining the haplogroup T) or in association with the m.13708G > A variant in the ND subunit 5 gene (in part defining the haplogroup J). However, a few subjects with other haplogroups can also present these variants (Herrnstadt et al. 2002) . Thus, in order to confirm the haplogroups of the subjects carrying the m.4216T > C and m.4917A > G variants, we screened additional J/T specific polymorphisms as previously described (AlvesSilva et al. 2000) .
For this study we excluded patients carrying the MIDD associated m.3243A > G variant. This was to ensure that the effects caused by this variant would not be a confounding factor for our conclusions. The method used for the screening of the m.3243A > G variant was as described by Katagiri et al. (1994) .
Statistical Methods
Data are presented as means ± SD or % (n). Variant frequencies in patients and control subjects were compared using the χ 2 test, likelihood ratio test, Fisher's exact test or odds ratio (OR). ANOVA or χ 2 tests were used to compare the clinical and laboratory characteristics among three groups of diabetic patients: 1. patients without the m.4216T > C and m.4917A > G variants; 2. patients with the m.4216T > C variant only (haplogroup J); and 3. patients with both the m.4216T > C and m.4917A > G variants (haplogroup T). When a difference among the groups was detected, pairwise comparisons or analyses of the normalized residuals were carried out, as appropriate. Multiple logistic regression analyses were performed to evaluate the association of different variables with the haplogroups J or T, as well as to control for possible confounding factors, whenever a statistically significant association was found in the univariate analyses. Separate analyses looked for the presence of haplogroup J and haplogroup T. Variables with a skewed distribution were logarithmically transformed before analyses and are presented as medians (range). All analyses were performed using the SPSS version 10.0 program, and a two-tailed probability value of P < 0.05 was considered significant.
Results
Frequencies of the m.4216T > C and m.4917A > G Variants and of the Haplogroups J and T amongst Type 2 Diabetic Patients and Control Subjects
The frequencies of the m.4216T > C and m.4917A > G variants and of the cluster J/T are shown in Table 1 . In the present study we observed that the frequencies of the m.4216T > C and m.4917A > G variants are higher in the diabetic patients than in the control subjects. Consequently, both haplogroups J and T are more frequent in the type 2 diabetic group as compared to the control group. We screened additional polymorphisms associated with the haplogroups J and T, to make sure that the subjects carrying the m.4216T > C and m.4917A > G variants really had one of these two haplogroups. Three patients presented the m.4917A > G variant only; thus they do not belong to the haplogroup T. In addition, we found three control subjects that, despite having the m.4216G > C variant, do not belong to haplogroup J. These six subjects were excluded from the analyses of frequencies of haplogroups J and T.
Influence of the m.4216T > C and m.4917A > G Variants and Haplogroups J and T on the Clinical and Laboratory Characteristics of Type 2 DM
The clinical and laboratory characteristics of type 2 DM were compared among three groups of patients (Table 2) When multiple logistic regression analyses were performed using age at patient's examination, gender, BMI and HOMA-insulin resistance as independent risk factors, and the presence of the haplogroup J or of the haplogroup T as the dependent variable, we observed that HOMA-insulin resistance remained significantly associated with haplogroups J and T, independent of the presence of the other variables used in the logistic regressions (Table 3) .
Discussion
Our study indicates that the m.4216T > C and m.4917A > G variants, and consequently the cluster J/T, are possibly associated with type 2 DM and HOMA-insulin resistance in Caucasian-Brazilian patients. The first concern regarding this finding is whether our results could be misleading due to undetected population stratification in our samples. However, we find this possibility unlikely: only Caucasian-Brazilian subjects were studied, and both type 2 diabetic patients and control subjects were recruited from the same hospitals. Thus, despite some degree of genetic admixture in the self-declared Data are shown as means ± SD, % or median (range).
a P for comparisons among the three groups. b HOMA (homeostasis model assessment)-insulin resistance was measured only in a subgroup of 120 patients not having insulin treatment.
c Statistically significant differences in means or% are indicated by different capital letters. Means and% which did not differ significantly at α < 0.05 are indicated by the same capital letter.
d Clear maternal history is the presence of maternal type 2 DM in three consecutive generations or through two consecutive generations with at least three affected individuals.
Table 3
Odds ratio adjusted by logistic regression for association with the haplogroup J or haplogroup T in type 2 diabetic patients Results are presented as odds ratio (95% Confidence Interval); P value.
Caucasian-Brazilian population being known (AlvesSilva et al. 2000) , it is hard to imagine that both groups could have different admixture levels. Additionally, an independent study carried out in the same patient and control groups (Carlessi et al. 2004) did not find statistically significant differences between these groups for a nuclear polymorphism (UCP2, uncoupling protein-2 gene, exon 8 insertion/deletion) for which Caucasian-Brazilians and African-Brazilians have significantly different frequencies (Daisy Crispim, unpublished results), similar to results observed in other populations (Yanovski et al. 2000) . Our findings on the frequencies of the m.4216T > C and m.4917A > G variants conflict with the report of Perucca-Lostanlen et al. (2000) in a French type 2 diabetic population. These authors found the m.4216T > C variant in 8.3% of the type 2 diabetic group and in 12.3% of the control group. They also reported that the m.4917A > G variant was present in 4.2% of the type 2 diabetic group and in 9.2% of the control group. One of the factors that could account for the discrepancies between our results and the findings of Perucca-Lostanlen et al. (2000) is the small number of patients analyzed in the latter study (24 type 2 diabetic patients and 65 control subjects). Alternatively, differences in genetics as well as environmental backgrounds between the Brazilian and French populations could be a reason why the m.4216T > C and m.4917A > G variants were only found to be associated with type 2 DM in the Brazilian population.
Unlike many pathogenic mutations the m.4216T > C and m.4917A > G variants are homoplasmic, which is generally considered to reflect a neutral variation. In fact, some studies have suggested that these variants are possibly neutral polymorphisms associated with the European specific cluster J/T (Finnila et al. 2001; Herrnstadt et al. 2002) . However, these variants have also been reported as associated with LHON (Carelli et al. 2003 ), Parkinson's disease (Ross et al. 2003) , the diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) syndrome (Hofmann et al. 1997 ) and multiple sclerosis (Kalman et al. 1995) . In the pathogenesis of LHON, they are thought to exacerbate the effects of the primary LHON mutations, but are not sufficient by themselves to cause visual loss, since they can be found both in LHON pedigrees (with primary mutations) and in healthy subjects mostly belonging to the cluster J/T (Torroni et al. 1997; Brown et al. 2002) . For example, 70.0% of the European patients carrying the primary T to C LHON mutation at np14484 belong to haplogroup J, while about 10.0% of healthy subjects belong to this haplogroup (Brown et al. 1997) .
There are scarce and controversial functional studies of the m.4216T > C and m.4917A > G variants. Vergani et al. (1995) , evaluating the mitochondrial respiratory function in cybrid cells of patients with primary LHON mutations, reported that in a specific mtDNA background (haplogroup J) the secondary m.4216T > C variant may act synergistically, increasing the severity of a defect in OXPHOS. In opposition, Lodi et al. (2000) found that the m.4216T > C variant did not further impair brain and skeletal muscle OXPHOS in subjects with the primary G to A LHON mutation at np11778, as assessed by phosphorus magnetic resonance spectroscopy. Moreover, mitochondrial activity in platelets from healthy subjects with haplogroups J or T did not differ from that found in subjects without these haplogroups (Carelli et al. 1999) . Additional studies are needed to clarify the functional role of the m.4216T > C and m.4917A > G variants, and also to investigate their interaction with nuclear and environmental factors.
We observed that patients of the cluster J/T present a more severe HOMA-insulin resistance as compared to patients not belonging to this cluster. Is there any biological plausibility for the association of cluster J/T with insulin resistance? Recent studies have shown that ATP availability in muscle has an important role in insulin sensibility (Lee, 2001; Kelley et al. 2002; Petersen et al. 2003 Petersen et al. , 2004 . Petersen et al. (2004) demonstrated that insulin resistance in the young offspring of type 2 diabetic patients is due to a dysregulation in intramyocellular fatty acid metabolism, which may be caused by an inherited defect in OXPHOS. Even the common m.16189T > C variant in the mitochondrial D-loop has been reported as being possibly associated with insulin resistance (Poulton et al. 1998) . Considering these studies it is conceivable that defects in the mitochondrial energy machinery could be associated with insulin resistance due to a variation in ATP concentration in muscle, possibly caused by the m.4216T > C and m.4917A > G variants. However, as implied by their occurrence in control subjects, these variants are not sufficient by themselves to cause noticeable insulin resistance and type 2 DM. Thus additional mtDNA and nuclear variants, as well as environmental risk factors, might be involved. We cannot exclude the possibility that these variants could be neutral polymorphisms within the cluster J/T and are only segregating with truly pathogenic mutations.
In conclusion, our results indicate an association of the cluster J/T (as suggested by analyses of the m.4216T > C and m.4917A > G variants) with insulin resistance and type 2 DM in Southern Brazil. However, since the m.4216T > C and m.4917A > G variants probably have only a subtle effect on mitochondrial function, they might be associated with other genetic or environmental factors in the onset of insulin resistance and type 2 DM. Further studies are required to confirm the biochemical effects of these variants in mitochondrial function and their role in the pathogenesis of the type 2 DM.
